Skip to main content

Advertisement

Log in

Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

IDH1 mutated glioblastoma (GB) has a better prognosis than IDH1 wildtype GB. However, it remains unknown whether patients (pts) with IDH1 mutated GB have a higher 6-month progression free survival (PFS6) or radiographic response (RR) rate on clinical trials for recurrence. Retrospective review of GB pts at MDACC between 2006 and 2012 identified 330 patients in recurrent GB trials. 93 patients (28 %) had either PFS6 or a complete/partial RR per RANO criteria. 49/93 (53 %) patients with PFS6 or a complete/partial RR had tumor tissue for IDH1 testing. A matched cohort of 49 patients on recurrent GB clinical trials that failed to achieve PFS6 or RR (also with tissue for IDH1 testing) was identified for comparison. IDH1 status was obtained in 92/98 (94 %) patients of which 17 (18 %) had an IDH1 mutation. PFS6 was seen in 26/49 (53 %) patients. IDH status was unknown in two of these patients. 5/24 (21 %) were IDH1 mutated compared to 5/24 (21 %) of their matched cohort without PFS6. RR was found in 47/49 (94 %) patients. IDH status was unknown in four of these patients. IDH1 mutation was present in 7/43 (16 %) patients with RR compared to 10/43 (23 %) in the matched cohort without RR (p = 0.48). Median OS for trials at first recurrence was 9.8 months for IDH1 wildtype GB vs. 19.32 months for IDH1 mutated GB (p = 0.14). IDH1 mutation status was not predictive of PFS6 or RR in recurrent GB trials for this data set. However, further examination in larger randomized prospective studies is needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359(5):492–507

    Article  CAS  PubMed  Google Scholar 

  2. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10): 987–96.

    Article  CAS  PubMed  Google Scholar 

  3. Scherer H (1940) Cerebral astrocytomas and their derivatives. Am J Cancer 40:159

    Google Scholar 

  4. Kleihues P, Ohgaki H (1999) Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncol 1(1):44–51

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Ohgaki H, Dessen P, Jourde B et al (2004) Genetic pathways to glioblastoma: a population-based study. Cancer Res 64(19):6892–6899

    Article  CAS  PubMed  Google Scholar 

  6. Theeler BJ, Yung WK, Fuller GN, De Groot JF (2012) Moving toward molecular classification of diffuse gliomas in adults. Neurology 79(18):1917–1926. doi:10.1212/WNL.0b013e318271f7cb

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Louis DN, Perry A, Burger P (2014) International Society of Neuropathology—Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 24(5):429

    Article  PubMed  Google Scholar 

  8. Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8):765–773. doi:10.1056/NEJMoa0808710

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science. 321(5897): 1807. doi:10.1126/science.1164382

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Labussiere M, Sanson M, Idbaih A et al (2010) IDH1 gene mutations: a new paradigm in glioma prognosis and therapy? Oncologist. 15(2): 196–199. doi:10.1634/theoncologist.2009-0218

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Ohgaki H, Kleihues P (2013) The definition of primary and secondary glioblastoma. Clin Cancer Res 19(4):764–772. doi:10.1158/1078-0432.CCR-12-3002

    Article  CAS  PubMed  Google Scholar 

  12. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H (2009) IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15(19):6002–6007. doi:10.1158/1078-0432.CCR-09-0715

    Article  CAS  PubMed  Google Scholar 

  13. Hartmann C, Hentschel B, Wick W et al (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120(6):707–718. doi:10.1007/s00401-010-0781-z

    Article  PubMed  Google Scholar 

  14. Sanson M, Marie Y, Paris S et al (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27(25):4150–4154. doi:10.1200/JCO.2009.21.9832

    Article  CAS  PubMed  Google Scholar 

  15. Wen P, Macdonald D, Reardon D et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963–1972. doi:10.1200/JCO.2009.26.3541

    Article  PubMed  Google Scholar 

  16. Taal W, Oosterkamp HM, Walenkamp AM et al (2014) Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 15(9):943–953. doi:10.1016/S1470-2045(14)70314-6

    Article  CAS  PubMed  Google Scholar 

  17. Watanabe T, Nobusawa S, Kleihues P et al (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174(4):1149–1153

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Rohle D, Popovici-Muller J, Palaskas N et al (2013) An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340(6132):626–630

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Ichimura K, Pearson DM, Kocialkowski S et al (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11(4):341–347. doi:10.1215/15228517-2009-025

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Sonoda Y, Kumabe T, Nakamura T et al (2009) Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci 100(10):1996–1998. doi:10.1111/j.1349-7006.2009.01270.x

    Article  CAS  PubMed  Google Scholar 

  21. Labussiere M, Boisselier B, Mokhtari K et al (2014) Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. Neurology 83:1200–1206

    Article  CAS  PubMed  Google Scholar 

  22. Eckel-Passow JE, Lachance DH, Molinaro AM (2015) Glioma Groups Based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372(26):2499–2508

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Zou Y, Xiao Bai H, Wang Z et al (2015) Comparison of immunohistochemistry and DNA sequencing for the detection of IDH1 mutations in gliomas. Neuro Oncol 17(3):477–478. doi:10.1093/neuonc/nou351

    PubMed  PubMed Central  Google Scholar 

  24. Mellai M, Piazzi A, Caldera V et al (2011) IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors. J Neurooncol 105(2):345–357

    Article  CAS  PubMed  Google Scholar 

  25. Catteau A, Girardi H, Monville F et al (2014) A new sensitive PCR assay for one-step detection of 12 IDH1/2 mutations in glioma. Acta Neuropathol Commun 2:58

    Article  PubMed  PubMed Central  Google Scholar 

  26. Loussouarn D, Le Loupp AG, Frenel JS et al (2012) Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas. Int J Oncol 40(6):2058–2062.

    CAS  PubMed  Google Scholar 

  27. Preusser M, Capper D, Hartmann C. (2011) Euro CNS research committe. IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee. Clin Neuropathol 30(5):217230.

    Article  CAS  PubMed  Google Scholar 

  28. Kruser TJ, Mehta MP, Kozak KR (2016) Identification of patients who benefit from bevacizumab in high-grade glioma—an easy question turned difficult: treat the scan or the patient? J Clin Oncol 34:1281–1282

    Article  PubMed  Google Scholar 

Download references

Funding

No funding was obtained for this project.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to John F. de Groot.

Ethics declarations

Conflict of interest

No conflict of interests to report.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 140 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mandel, J.J., Cachia, D., Liu, D. et al. Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma. J Neurooncol 129, 147–154 (2016). https://doi.org/10.1007/s11060-016-2157-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-016-2157-2

Keywords

Navigation